You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Chimeric Antigen Receptor (CAR) T cells

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Trial (TmPSMA-02 CAR T Cells)

Not yet recruiting
  • Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
  • TmPSMA-02 CAR T Cells
  • (no location specified)
Sep 13, 2023

Metastatic Castration-resistant Prostate Cancer Trial (TmPSMA-02)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • TmPSMA-02
  • (no location specified)
Aug 3, 2022

B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent Trial in Maywood (Fludarabine,

Active, not recruiting
  • B-Cell Acute Lymphoblastic Leukemia, Adult
  • +2 more
  • Maywood, Illinois
    Loyola University
Aug 11, 2022

Non Hodgkin Lymphoma Trial in Aurora (UCD19 CAR T Cells)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • UCD19 CAR T Cells
  • Aurora, Colorado
    University of Colorado Hospital
Sep 1, 2022

B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)

Recruiting
  • B-Cell Lymphoma
  • +4 more
  • 19(T2)28z1xx TRAC T cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023

Diffuse Midline Glioma, H3 K27M-Mutant Trial (GD2 CAR T cells)

Not yet recruiting
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • GD2 CAR T cells
  • (no location specified)
Sep 15, 2022

Acute Lymphocytic Leukemia Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Recruiting
  • Acute Lymphocytic Leukemia
  • CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
  • Tianjin, Tianjin, China
    Hematology Hospital, Chinese Academy of Medical Sciences
Feb 5, 2023

Platinum-Resistant Ovarian Carcinoma Trial in Duarte (Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine)

Recruiting
  • Platinum-Resistant Ovarian Carcinoma
  • Chimeric Antigen Receptor T-cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jul 21, 2022

Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Acute Lymphoid Leukemia
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

T-cell Non-Hodgkin's Lymphoma Trial (CD147- CAR T cells)

Not yet recruiting
  • T-cell Non-Hodgkin's Lymphoma
  • CD147- CAR T cells
  • (no location specified)
Aug 1, 2022

Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL Trial in Calgary, Edmonton (autologous CD19-directed

Recruiting
  • Relapsed Non Hodgkin Lymphoma
  • +2 more
  • autologous CD19-directed chimeric antigen receptor (CAR) T-cells
  • Calgary, Alberta, Canada
  • +5 more
Jul 18, 2022

Neuroblastoma Trial (GD2 CAR T cells)

Not yet recruiting
  • Neuroblastoma
  • GD2 CAR T cells
  • (no location specified)
Aug 5, 2023

B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma Trial in Stanford (Fludarabine, Cyclophosphamide, Autologous

Suspended
  • B Cell Lymphoma
  • +2 more
  • Stanford, California
    Stanford Medical Center
Sep 8, 2022

Recurrent Glioblastoma, Refractory Glioblastoma Trial in Hangzhou, Huzhou, Ningbo (Temozolomide, B7-H3 CAR-T)

Recruiting
  • Recurrent Glioblastoma
  • Refractory Glioblastoma
  • Hangzhou, Zhejiang, China
  • +2 more
Dec 25, 2022

Lupus Erythematosus, Systemic Trial in Berlin (CC-97540, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Lupus Erythematosus, Systemic
  • Berlin, Germany
    Local Institution - 0025
May 22, 2023

Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Taiyuan (CEA-targeted CAR-T cells)

Recruiting
  • Gastric Cancer
  • +6 more
  • CEA-targeted CAR-T cells
  • Taiyuan, Shanxi, China
  • +1 more
Aug 24, 2023

Neuroendocrine Tumor (NET), Colorectal Cancer (CRC) Trial (CHM-2101 CAR-T cells)

Not yet recruiting
  • Neuroendocrine Tumor (NET)
  • Colorectal Cancer (CRC)
  • CHM-2101 CAR-T cells
  • (no location specified)
Sep 20, 2023

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in Duarte

Not yet recruiting
  • Castration-Resistant Prostate Carcinoma
  • +2 more
  • Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
  • +7 more
  • Duarte, California
    City of Hope Medical Center
Apr 5, 2023

Ependymoma Trial in New York (HER2 Specific CAR T Cell)

Recruiting
  • Ependymoma
  • HER2 Specific CAR T Cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Apr 6, 2022

Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma Trial in Duarte (Chlorotoxin

Recruiting
  • Recurrent Glioblastoma
  • +3 more
  • Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)
  • Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)
  • Duarte, California
    City of Hope Medical Center
Feb 25, 2022

Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,

Recruiting
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Manufactured Anti-BCMA CAR-T cells
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jan 6, 2023

Advanced Sarcoma Trial (NKG2D-CAR memory T cell)

Not yet recruiting
  • Advanced Sarcoma
  • NKG2D-CAR memory T cell
  • (no location specified)
Oct 17, 2023

Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Wuhu (CEA-targeted CAR-T cells)

Recruiting
  • Gastric Cancer
  • +7 more
  • CEA-targeted CAR-T cells
  • Wuhu, Anhui, China
    The First Affiliated Hospital of Wannan Medical College
Nov 9, 2023

Sarcoma, HER-2 Protein Overexpression Trial in Houston (cells, Pembrolizumab Injectable Product, Nivolumab Injectable Product)

Recruiting
  • Sarcoma
  • HER-2 Protein Overexpression
  • cells
  • +3 more
  • Houston, Texas
    Texas Children's Hospital
Dec 8, 2021